Topiramate blocks kainate-evoked cobalt influx into cultured neurons

Epilepsia

Volumn 41, Issue SUPPL. 1, 2000, Pages 45-47

  Skradski, Shana ^a   White, H Steve ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Antiepileptic drugs; Epilepsy; Kainate; Topiramate

Indexed keywords

EID: 0034115767     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb02171.x     Document Type: Article

References (19)

1. Coulter DA, Sombati S, DeLorenzo RJ. Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents. Epilepsia 1995;36(suppl 3):S40.
2. Severt L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia 1995;36(suppl 4):S38.
3. Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1)510-6.
4. Pruss RM, Akeson RL, Racke MM, Wilburn JL. Agonist-activated cobalt uptake identifies divalent cation-permeable kainate receptors on neurons and glial cells. Neuron 1991;7:509-18.
5. Parks TN, Artman LD, Alasti N, Nemeth EF. Modulation of N-methyl-D-aspartate receptor-mediated increases in cytosolic calcium in cultured rat cerebellar granule cells. Brain Res 1991;552: 13-22.
6. Chapman AG, Smith SE, Meldrum BS. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res 1991;9:92-6.
7. Durmiller N, Graggs M, Meldrum BS. The effect of the non-NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res 1994; 17:167-74.
8. Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 1993;14:325-31.
9. Smith S, Durmuller N, Meldrum BS. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anti-convulsants in two animal models of reflex epilepsy. Eur J Pharmacol 1991;201:179-83.
10. Yamaguchi S-I, Donevan SD, Rogawski MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 1993;15:179-84.
11. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory epilepsy. Epilepsy Res 1996;25:217-24.
12. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
13. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
14. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
15. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996;46:1678-83.
16. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G, Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52: 1882-87.
17. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu S-C, Pledger G, Topiramate UP Study Group. A double-blind randomized trial of topiramate as adjunctive therapy for partial onset seizures in children. Neurology 1999;52:1338-44.
18. Biton V, Montouris GC, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G, Topiramate YTC Study Group. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-37.
19. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31-108.